← Leaderboards
Ronald G Alvarez
University Of Alabama At Birmingham
$789,611
Attributed
$789,611
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$789,611 · 3
By mechanism
M01$789,611 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- David T Curiel$31,690,411
- Edward E Partridge$43,798,134
- Natalia Y Kedishvili$11,245,175
- Albert F Lobuglio$1,259,317
- Peter D Emanuel$39,860,242
Others in their field
Top investigators on “Female”
- Philip J Disaia · University Of California Irvine$140,003,514
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$103,542,269
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,372,214
- Myron S Cohen · Family Health International$101,800,876
- Walter John Curran · Thomas Jefferson University$57,608,324
- Gregory S Boebinger · Florida State University$55,673,680
Research focus
FemaleHuman Therapy EvaluationHuman SubjectClinical ResearchNeoplasm /Cancer ChemotherapyAdenoviridaeGene TherapyTransfection /Expression VectorClinical TrialsGanciclovirTumor Suppressor GenesGenetic ManipulationHerpesviridaeChemopreventionCervix NeoplasmsAntineoplasticsReproductive System Disorder ChemotherapyRetinoateWomen'S HealthCytotoxicityDosageProtooncogeneImmunogeneticsTransfection
Grant awards (7)
MOLECULAR CHEMOTHERAPY FOR OVARIAN CANCER$175,256
M01 · FY2002 · RR
9 CIS RETINOIC ACID IN CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 &3$175,256
M01 · FY2002 · RR
MOLECULAR CHEMOTHERAPY FOR OVARIAN CANCER$175,256
M01 · FY2001 · RR
9 CIS RETINOIC ACID IN CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 &3$175,256
M01 · FY2001 · RR
MOLECULAR CHEMOTHERAPY FOR OVARIAN CANCER$29,529
M01 · FY2000 · RR
9 CIS RETINOIC ACID IN CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 &3$29,529
M01 · FY2000 · RR
ADENOVIRUS ENCODING ANTI ERBB 2 IN RECURRENT OVARIAN CANCER$29,529
M01 · FY2000 · RR